Clinical trial · Interventional
Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer
Neoadjuvant S1, Oxaliplatin, and Docetaxel (SLOT) Versus S1, Oxaliplatin(SOX) in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer
NCT02512380CI-TRIAL-00018791unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
gastric cancer is a highly aggressive malignancy with a poor overall outcome. The purpose of this study is to evaluate the 5-year survival of neoadjuvant S1, oxaliplatin, and docetaxel (SLOT) versus S1, oxaliplatin(SOX) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Adenocarcinoma | Gastric Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel;oxaliplatin;s1 | Drug | — | UNRESOLVED |
| oxaliplatin;s1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- SLOT group
- description
- 4 cycles preoperative chemotherapy with Docetaxel+oxaliplatin+s1 . Gastric resection. 6 cycles adjuvant chemotherapy with sequential oxaliplatin+s1 or oxaliplatin+s1,then s1 for 6 months。
- interventionNames
- Drug: Docetaxel;oxaliplatin;s1
- type
- ACTIVE_COMPARATOR
- label
- SOX group
- description
- 3 cycles preoperative chemotherapy with oxaliplatin+s1. Gastric resection. 4 cycles adjuvant chemotherapy with sequential oxaliplatin+s1
- interventionNames
- Drug: oxaliplatin;s1
Primary outcomes (1)
- measure
- 5 year overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven gastric or GE junction adenocarcinoma; * Age: 18 to 70; * ECOG 0-2; * Adenocarcinoma of the stomach or GE junction according to staging classification TNM Scannographic: T3-4 N0/N + M0 ; * Completion of baseline quality of life questionnaire * Adequate bone marrow functions (ANC ≥ 1,500/ul, blood platelet ≥ 100,000/ul, haemoglobin ≥ 10g/dl); * Adequate renal functions(serum creatinine ≤ 1.5mg/dl) * liver functions (serum bilirubin ≤ 1.5UNL, AST/ALT ≤ 3 times(normal value) * Written informed consent Exclusion Criteria: * Previous chemotherapy; * Active infection requiring antibiotics * Pregnant, lactating women * Psychiatric illness, epileptic disorders * Concurrent systemic illness not appropriate for chemotherapy * History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma
References
Publications (0)
Data not yet available
No reference posted for this study.